Perry C. Siatis - Oct 17, 2022 Form 3 Insider Report for AbbVie Inc. (ABBV)

Role: EVP, GC and Secretary
Signature: Steven L. Scrogham, attorney-in-fact for Perry C. Siatis
Stock symbol: ABBV
Transactions as of: Oct 17, 2022
Transactions value $: $0
Form type: 3
Date filed: 10/27/2022, 05:01 PM
Next filing: Feb 21, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	ABBV	Common Stock, $0.01 par value						10.4K	Oct 17, 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	ABBV	Option (Right to buy)							Oct 17, 2022	Common Stock	7.36K	$93.50	Direct	F2
holding	ABBV	Option (Right to buy)							Oct 17, 2022	Common Stock	7.04K	$105.92	Direct	F3
holding	ABBV	Option (Right to buy)							Oct 17, 2022	Common Stock	8.76K	$144.54	Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These securities represent restricted stock units granted under the AbbVie Amended and Restated 2013 Incentive Stock Program. They vest in full on February 17, 2025, and include the right to have stock withheld for tax purposes.
F2	Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable as to 7,365 shares on 2/20/2021 and as to 7,365 shares on 2/20/2022, and will become exercisable as to 7,364 shares on 2/20/2023.
F3	Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable as to 3,250 shares on 2/18/2022, and will become exercisable as to 3,250 shares on 2/18/2023 and as to 3,519 shares on 2/18/2024.
F4	Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option will become exercisable as to 2,919 shares on 2/17/2023, as to 2,919 shares on 2/17/2024 and as to 2,918 shares on 2/17/2025.